ArticleFrontiers in pharmacology2018
A
Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Modulation of Antitumor Immunity and the Tumor Microenvironment byInternational journal of molecular sciences · 2026Article
- Protective effects ofCytotechnology · 2025Article
- The Co-Delivery of Natural Products and Small RNAs for Cancer Therapy: A Review.Molecules (Basel, Switzerland) · 2025Review
- Promising leads against lung cancer from the plants in Lamiaceae family.BioImpacts : BI · 2025Review
- Network pharmacology and transcriptomics reveal the mechanisms of FFBZL in the treatment of oral squamous cell carcinoma.Frontiers in pharmacology · 2024Article
- Molecular Assessment ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Systems pharmacology to reveal multi-scale mechanisms of traditional Chinese medicine for gastric cancer.Scientific reports · 2021Article
- Article
- Systems pharmacology dissection ofAging · 2021Article
- Potential Role of Traditional Chinese Medicines by Wnt/β-Catenin Pathway Compared With Targeted Small Molecules in Colorectal Cancer Therapy.Frontiers in pharmacology · 2021Review
- A Network Pharmacology Study on the Molecular Mechanisms of FDY003 for Breast Cancer Treatment.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- LncRNA SNHG19 Promotes the Development of Non-Small Cell Lung CancerFrontiers in oncology · 2021Article
- Systems pharmacology reveals the mechanism of activity of Physalis alkekengi L. var. franchetii against lipopolysaccharide-induced acute lung injury.Journal of cellular and molecular medicine · 2020Article
- Network Pharmacology-Based Investigation of the System-Level Molecular Mechanisms of the Hematopoietic Activity of Samul-Tang, a Traditional Korean Herbal Formula.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Investigation of the Lipid-Lowering Mechanisms and Active Ingredients of Danhe Granule on Hyperlipidemia Based on Systems Pharmacology.Frontiers in pharmacology · 2020Article
- Antitumor Effects and the Compatibility Mechanisms of Herb PairFrontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) is the most ordinary type of lung cancer which leads to 1/3 of all cancer deaths. At present, cytotoxic chemotherapy, surgical resection, radiation, and photodynamic therapy are the main strategies for NSCLC treatment. However, NSCLC is relatively resistant to the above therapeutic strategies, resulting in a rather low (20%) 5-year survival rate. Therefore, there is imperative to identify or develop efficient lead compounds for the treatment of NSCLC. Here, we report that the herb
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.